Table 6.

Effects of exercise intervention on secondary outcomes (number of infections per child).

Allogeneic-HSCT
	Control Group (n = 39)		Exercise Group (n = 47)
Outcome	Unadjusted	Adjusted *	Unadjusted	Adjusted *	Unadjusted between-group Difference p-Value	Adjusted * between-group Difference p-Value
Number of infections after HSCT	2 ± 0 (1, 2)	2 ± 0 (1, 3)	1 ± 0 (1, 1)	2 ± 0 (1, 2)	0.005	0.023
Number of viral infections after HSCT	1 ± 0 (1, 1)	1 ± 0 (0, 2)	0 ± 0 (0, 1)	1 ± 0 (0, 1)	0.005	0.083
Number of bacterial infections after HSCT	0 ± 0 (0, 1)	1 ± 0 (0, 1)	0 ± 0 (0, 1)	1 ± 0 (0, 1)	0.947	0.942
Number of fungal infections after HSCT	1 ± 0 (0, 1)	1 ± 0 (0,1)	0 ± 0 (0, 0)	0 ± 0 (0, 1)	0.022	0.026
Autologous-HSCT
	Control Group (n = 14)		Exercise Group (n = 18)
	Unadjusted	Adjusted **	Unadjusted	Adjusted **	Unadjusted between-group Difference p-value	Adjusted ** between-group Difference p-value
Number of infections after HSCT	1 ± 0 (1, 2)	1 ± 0 (1, 2)	1 ± 0 (0, 1)	1 ± 0 (0, 1)	0.273	0.213
Number of viral infections after HSCT	1 ± 0 (0, 1)	0 ± 0 (0, 1)	0 ± 0 (0, 1)	0 ± 0 (0, 1)	0.678	0.959
Number of bacterial infections after HSCT	0 ± 0 (0, 1)	1 ± 0 (0, 1)	0 ± 0 (0, 1)	0 ± 0 (0, 1)	0.525	0.230
Number of fungal infections after HSCT	0 ± 0 (0, 0)	0 ± 0 (0, 0)	0 ± 0 (0, 0)	0 ± 0 (0, 0)	0.518	0.728

All data are expressed as mean ± SEM (95% confidence interval). The control group was used as reference for regression analyses. We corrected all the analyses for multiple comparisons with the Bonferroni method; that is, dividing 0.05 by the number of comparisons. Thus, the threshold p-value for statistical significance was set at 0.0125 (=0.05/4) for both allogeneic and autologous HSCT and significant differences between groups are in bold. Abbreviations: CI, confidence interval; HSCT, hematopoietic stem cell transplantation; Symbols: * adjusted by group (i.e., exercise or control), graft manipulation (i.e., manipulated or unmanipulated), age at HSCT, sex differences between donor and recipient (i.e., yes or no), conditioning regimen (i.e., myeloablative or nonmyeloablative), source (i.e., peripheral blood or umbilical cord) and origin (i.e., parent, sibling or unrelated donor) of donor cells, GvHD prophylaxis (i.e., cyclosporine or cyclosporine + methylprednisolone), disease status (i.e., 1st, 2nd, >2nd CR or not in remission) and human leukocyte antigens match status (i.e., HLA-matched and related, HLA-matched and unrelated, or HLA-mismatched (related or unrelated)); ** adjusted by group, age at HSCT, conditioning regimen, source of donor cells and disease status (those mentioned above for allo-HSCT).